Navigation Links
Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs
Date:12/3/2009

LONDON, Dec. 3 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) providing clinical development and staffing services in Europe, the Americas and Asia, today announces the appointment of Dr. Sharon Moore as Executive Vice President, Global Quality & Medical Affairs. Dr. Moore is based at Chiltern's Bristol, Tennessee, USA office.

Dr. Moore is a physician with 15 years of industry experience. Prior to joining Chiltern, Sharon served as a pharmacovigilance physician and practiced medicine, served as an investigator, was a member of an Institutional Review Board and authored several publications. She joined CTMS, a US CRO, in 1998. Sharon has served with Chiltern since the acquisition of CTMS in 2007 as Global Head of Quality Assurance and Executive Director, Medical Affairs. Sharon has Masters in Public Health (MPH) and Business Administration (MBA), holds an active medical license, and is a Certified Physician Investigator (CPI) through the Academy of Pharmaceutical Physicians and Investigators (APPI).

"I am delighted to appoint Dr. Moore to lead our global quality and medical functions and to have her join our Group Executive Board," stated Glenn Kerkhof, CEO of Chiltern. This is a key scientific appointment and Dr. Moore brings a wealth of experience which will enhance our operational delivery and consultative approach for our clients."

Dr. Moore commented, "I am excited about the opportunity to represent our global QA, Medical and Pharmacovigilance functions. We work in a dynamic environment with increasing complexity of clinical trials and growing importance of safety surveillance. Our teams are working to strengthen our services and to prepare for new medical developments."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 28 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.


For More Information:

Natalie Chong, Chiltern International  Sue Ojanen, Chiltern International
 Ltd.                                   Inc.
171 Bath Road                          1241 Volunteer Parkway
Slough, Berkshire SL1 4AA, UK          Bristol, TN 37620, USA
Tel:  44 (0) 1753 512 000              Tel:  1 (423) 968 9533
Email: natalie.chong@chiltern.com      Email: sue.ojanen@chiltern.com

SOURCE Chiltern


'/>"/>
SOURCE Chiltern
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Marco Romano, MD Joins Chiltern as Medical Director, Europe
2. Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
3. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
4. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
5. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
6. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
7. Chiltern Wins Top Prize
8. Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas, April 14 - 16, 2008.
9. Chiltern Opens a New Office in Russia
10. Chiltern Announces New Expansion in Portugal
11. Chiltern Expands Its Global Reach to Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard ... businesses and organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released ... own QMS, with a deadline of September 2018. , As described in ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... developed by a neurosurgeon, has received a big bump in sales after ... Booster is currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, RonnieColemanNutrition.com, RevNutrition.com ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... has agreed to serve as strategic adviser to the animal healthcare division ... of the Bridge Animal Referral Center (BARC) in Edmonds, Washington, which specializes ...
(Date:9/19/2017)... ... September 19, 2017 , ... First Choice Emergency ... named Dr. Howard Ng, as the new Medical Director of its Pflugerville- FM 685 ... facility Medical Director of our Pflugerville- FM 685 location,” said Dr. Stephen Van Roekel, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team ... importance of making a distinct rather than generic impression in the job market if ... through a stack of resumes knows that the first impression they give off is ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
Breaking Medicine Technology: